quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:04:56·17d
SECFiling
Alkermes plc logo

SEC Form DEF 14A filed by Alkermes plc

ALKS· Alkermes plc
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ALKS
    Alkermes plc
    Health Care

Recent analyst ratings

  • Feb 24UpdateWolfe Research$45.00
  • Nov 11UpdateTruist$50.00
  • Sep 26UpdateRBC Capital Mkts$44.00
  • Sep 3UpdateWells Fargo$44.00
  • Jul 15UpdateGoldman$43.00
  • Jun 17UpdateUBS$42.00

Related

  • PR2d
    Alkermes to Report First Quarter Financial Results on May 5, 2026
  • PR8d
    Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
  • PR10d
    Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
  • INSIDER10d
    SEC Form 4 filed by Lurker Nancy
  • INSIDER17d
    SEC Form 4 filed by Gaffin David Joseph
  • SEC17d
    SEC Form DEFA14A filed by Alkermes plc
  • INSIDER22d
    SEC Form 4 filed by Hopkinson Craig C.
  • SEC22d
    SEC Form 144 filed by Alkermes plc
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022